Yes, I agree, if both n and rGBM are supported by the trial data, which makes sense based on the n and rGBM tumor profiles (pre and post mutation) shared in multiple publications and all of the LL commentary, DCVax-L could be a sizable opportunity for GBM. The only question is whether DCVax-L can impact patients sufficiently without resections upon progression.
Market Data 
Markets 
AI
